PD-L1 blockade enhances anti-tumor efficacy of NK cells

Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade...

Descripción completa

Detalles Bibliográficos
Autores principales: Oyer, Jeremiah L., Gitto, Sarah B., Altomare, Deborah A., Copik, Alicja J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205063/
https://www.ncbi.nlm.nih.gov/pubmed/30377572
http://dx.doi.org/10.1080/2162402X.2018.1509819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205063/
https://www.ncbi.nlm.nih.gov/pubmed/30377572
http://dx.doi.org/10.1080/2162402X.2018.1509819

Ejemplares similares